Clinical Lymphoma Myeloma & Leukemia

Papers
(The H4-Index of Clinical Lymphoma Myeloma & Leukemia is 19. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-01-01 to 2026-01-01.)
ArticleCitations
SOHO State of the Art Updates and Next Questions | Approach to BCR::ABL1-Like Acute Lymphoblastic Leukemia38
Corrigendum to “OAB-005: Update of safety and efficacy of Isatuximab short-duration fixed-volume infusion plus Bortezomib, Lenalidomide, and Dexamethasone combined therapy for NDMM ineligible/with no 36
P-112 Fall Risk Assessment and Fall Prevention in Patients With Multiple Myeloma: First Results of the MYFALL-Trial35
P-154 Multidisciplinary, Patient-Centric Bone Disease Management in Multiple Myeloma – a Single-Centre Experience31
P-186 Identifying a New Risk-Stratification Strategy by Including Single-Cell Biomarkers in Multiple Myeloma30
P-309 Diagnostic Challenges in Systemic Amyloidosis: Exploring the Impact of Mass Spectrometry in a Middle-Income Country Cohort28
P-330 Stem Cell Mobilization Strategy With Pegilgrastim for Stem Cell Transplantation for Multiple Myeloma: A Direct Cost Comparison28
P-202 Risk Factors Predicting Early Relapse for Newly Diagnosed Multiple Myeloma Patients Treated with Front-Line VRD Regimen28
OA-27 Para-Medullary (PMD) and Extra-Medullary (EMD) Myeloma Demonstrate Increased Copy Number Aberration, Mutational Burden, Structural Variants and Genomic Complexity Compared to Marrow-Based Myelom26
P-342 Impact of Achieving <VGPR With Dara-RVD Induction Therapy in Newly Diagnosed Multiple Myeloma (NDMM) Patients26
P-012 Real-World Safety and Early Efficacy of Talquetamab in Patients with Heavily-Pretreated Relapsed/Refractory Multiple Myeloma24
P-455 Survey of multiple myeloma (MM) patients and healthcare professionals (HCPs) on the relevance of existing health quality-of-life (QoL) questionnaires (QoLQ) to real-world QoL issues of MM patien21
P-113 An Artificial Intelligence-Based 3D-Segmentation Assessment of Sarcopenia Utilizing Whole-Body Computed Tomography in Patients With Multiple Myeloma21
P-068 Developing Novel DKK1-A2 CAR-T Cell Therapy for Myeloma and Other Hematologic Malignancies21
P-139 Impact of melphalan staggered dosing prior to autologous hematopoietic cell transplantation for multiple myeloma patients20
P-100 Prevalence of monoclonal gammopathies in adult Uruguayan population20
MM-731 Prognostic Implications of Immune Paralysis in Newly Diagnosed Multiple Myeloma19
Management Challenges in Patients with Treatment-Free Remission of Chronic Myeloid Leukemia19
OA-38 Physical activity interventions to improve functional performance in patients with multiple myeloma19
Demographic Characteristics of Hospitalized Patients With History of Multiple Myeloma in Remission: Insights From National Inpatient Sample 202119
MPN-153 A Phase 1b Trial of DISC-0974, an Antihemojuvelin Antibody, in Participants With Myelofibrosis and Anemia19
IBCL-381 Studying the Impact of CD38 Expression on Extracellular Adenosine and Its Connection With the PD1/PDL1 Axis in Mature B-Cell Lymphoma Patients19
0.25461292266846